A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.
“The microbiome is a highly complex and diverse community of microorganisms living in and on the human body,” describes Dr. Kate Markey, Assistant Professor in the Translational Science and ...
Groundbreaking research in The Journal of Molecular Diagnostics shows that analysis of specific patterns of cell-free DNA ...
Cell-free DNA (cfDNA) has emerged as a powerful biomarker for monitoring allograft health and detecting rejection in solid organ transplantation. Since 2022, the Paris Transplant Group-PITOR has ...
In 107 patients, 48.6% of those who received unusual or nonreportable clinical cfDNA-sequencing results had an occult cancer, reported Diana W. Bianchi, MD, of the Eunice Kennedy Shriver National ...
Small cell lung cancer (SCLC) remains a challenging cancer type to treat effectively. While patients initially respond to chemotherapy and immunotherapies, the disease almost always returns, often ...
Researchers combined protein biomarkers, cfDNA analysis, and machine learning to open opportunities for early-stage ovarian cancer screening and diagnostics. The cfDNA fragmentome is a genome-wide ...
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial Our findings revealed a ...
When cells expire, they leave behind an activity log of sorts: RNA expelled into blood plasma that reveals changes in gene expression, cellular signaling, tissue injury and other biological processes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results